Key Events

Nov 2010

• CanBas selected as a presenting company at 16th Annual BIO-Europe2010 International Partnering Conference in Munich, Germany. Representing the first company to present in the Cancer track on November 17, 2010, CEO Takumi Kawabe delivers a presentation on lead product CBP501 as a clinical stage oncology opportunity
  See CanBas Bio-Europe 2010 Presentation

Sept 2010

• Abstract presented at 10th International Conference of the International Mesothelioma Interest Group (IMIG2010) on “Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM)”
  Read IMIG2010 abstract

June 2010

• CanBas and Takeda to Terminate Collaboration for CBP501 for the Treatment of Cancer

Sept 2009

• Completed Initial Public Offering on Tokyo Stock Exchange Mothers (M-4575)

Jun 2009

• Initiated US Phase II clinical study of CBP501, in concomitant use with Cisplatin and Pemetrexed, for treatment of patients with Non-small Cell Lung Cancer (“NSCLC”).

Jun 2009

• Initiated preclinical study of CBS9106 (small molecule)

Nov 2008

• Initiated preclinical study of CBS9106 (small molecule)

Nov 2008

• Initiated US Phase II clinical study of CBP501, in concomitant use with Cisplatin and Pemetrexed, for treatment of patients with Malignant Pleural Mesothelioma (“MPM”)

Oct 2007

• Initiated US Phase I clinical study of CBP501 in combination use with Cisplatin.

Mar 2007

• CanBas and Takeda to Sign the Collaboration Agreement for Investigational Compounds for Treatment of Cancer

Feb 2006

• Patent approval for CBP501 (US)